High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study)
Authors:
- F. Navarro-SarabiaFNF. Navarro-Sarabia
- J. L. Fernandez-SueiroJFJ. L. Fernandez-Sueiro
- J. C. Torre-AlonsoJTJ. C. Torre-Alonso
- J. GratacosJGJ. Gratacos
- R. QueiroR. Queiro
- C. GonzalezC. Gonzalez
- E. LozaELE. Loza
- L. LinaresLLL. Linares
- P. ZarcoPZP. Zarco
- X. JuanolaXJX. Juanola
- J. Roman-IvorraJRJ. Roman-Ivorra
- E. Martin-MolaEME. Martin-Mola
Open Access
- 23 June 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 50 (10) , 1828-1837
Abstract
Etanercept 50 mg a week is approved in the treatment of AS. Increasing the etanercept dose to 100 mg/week improves efficacy in cutaneous psoriasis, a clinical manifestation related to the spondylarthritis family, while maintaining its safety profile. The purpose of this study was to evaluate the efficacy and safety of etanercept 100 vs 50 mg/week in patients with AS. Adult patients with AS were randomized to receive etanercept 50 mg twice a week (biw), or etanercept 50 mg once a week (qw) for 12 weeks. The primary efficacy endpoint was Ankylosing Spondylitis Assessment Study (ASAS20) response at Week 12; secondary endpoints included ASAS40, ASAS50, ASAS70 and ASAS5/6 responses, partial remission and quality of life. Safety was assessed until 15 days after the last visit. A total of 108 patients were randomly selected and treated, 54 in each arm. At 12 weeks, ASAS20 response was achieved by 34 (71%) out of 48 patients of the etanercept 50 mg biw group and by 37 (76%) out of 49 patients of the etanercept 50 mg qw group (not statistically significant differences). Other efficacy variables improved significantly over time, but not between treatment groups. Fifty-six patients experienced at least one adverse event (generally, infections and infestations, gastrointestinal disorders and injection site reactions), most of them mild or moderate. High-dose (100 mg/week) etanercept in the treatment of AS for 12 weeks is as safe as the standard dose (50 mg/week). However, it does not significantly increase its efficacy. Trial Registration. Clinicaltrials.gov, http://clinicaltrials.gov/, NCT00873730.Keywords
This publication has 31 references indexed in Scilit:
- Etanercept in the Longterm Treatment of Patients With Ankylosing SpondylitisThe Journal of Rheumatology, 2009
- Developments in the scientific and clinical understanding of the spondyloarthritidesArthritis Research & Therapy, 2009
- Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugsArthritis & Rheumatism, 2008
- Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitisAnnals of the Rheumatic Diseases, 2008
- Ankylosing spondylitisThe Lancet, 2007
- Concepts and epidemiology of spondyloarthritisBest Practice & Research Clinical Rheumatology, 2006
- ASAS/EULAR recommendations for the management of ankylosing spondylitisAnnals of the Rheumatic Diseases, 2006
- Persistent clinical response to the anti-TNF-α antibody infliximab in patients with ankylosing spondylitis over 3 yearsRheumatology, 2005
- Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: A Department of Veterans Affairs cooperative studyArthritis & Rheumatism, 1999
- THE COURSE OF ESTABLISHED ANKYLOSING SPONDYLITIS AND THE EFFECTS OF SULPHASALAZTh OVER 3 YEARSRheumatology, 1993